<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04567251</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00102684</org_study_id>
    <nct_id>NCT04567251</nct_id>
  </id_info>
  <brief_title>Survivorship Study of Cancer Patients Who Received Cranial Radiation Therapy</brief_title>
  <acronym>SPiRiT</acronym>
  <official_title>Survivorship Study of Cancer Patients Who Received Cranial Radiation Therapy: Focus on Health-Related Quality of Life and Cognition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Varian Medical Systems</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this randomized, placebo-controlled, double-blind study are to 1)&#xD;
      assess whether or not Namzaric® improves cognitive function in cancer survivors who received&#xD;
      prior brain irradiation as part of their standard of care therapy and 2) assess the&#xD;
      feasibility of using a digital symptom tracking application focused on Health Related Quality&#xD;
      of Life (HRQoL) and cognition in cancer survivors who received brain irradiation. Exploratory&#xD;
      objectives include assessing longitudinally the effect of Namzaric® on Patient Reported&#xD;
      Outcomes (PROs) as reported in the clinic, including measures of health-related quality of&#xD;
      life, cognition, and financial toxicity and evaluating the safety and tolerability of&#xD;
      administering Namzaric® to cancer survivors who have received prior irradiation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who may participate in the study are cancer survivors who received cranial&#xD;
      irradiation for conditions including, but not limited to: primary brain tumors, brain&#xD;
      metastases, patients with lung cancer receiving prophylactic brain irradiation, and long-term&#xD;
      survivors of pediatric cancers. Up to 102 patients will be randomized 1:1 so half the&#xD;
      patients receive Namzaric® and half receive placebo. Patients on both arms will be taking&#xD;
      Namzaric® or placebo for 17 weeks, including dose-escalation and tapering. Patients will use&#xD;
      a symptom monitoring app, Noona® Healthcare Mobile PRO Application, to identify real-time&#xD;
      select HRQoL and cognitive symptoms during Namzaric® vs placebo therapy. Patients will be&#xD;
      instructed to log symptoms as often as relevant using their own personal devices, as well as&#xD;
      be prompted to fill out the Patient-Reported Outcomes Measurement Information System Global&#xD;
      Health Screen (PROMIS Global Health-10) during treatment (weeks 9 and 14). There will be no&#xD;
      patient follow-up after completing or discontinuing the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Namzaric® on cognition among cancer survivors who received brain irradiation</measure>
    <time_frame>Baseline, 15 weeks</time_frame>
    <description>Mean change between baseline and 15 weeks in the Brief Cognitive Assessment (BAC) composite cognitive score within each treatment group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of using a digital symptom tracking application on HRQoL and cognition in cancer survivors who received brain irradiation</measure>
    <time_frame>Baseline, 15 weeks</time_frame>
    <description>A percentage of patients returning for their 15 week clinic appointment who initiate a PROMIS questionnaire via the mobile application at weeks 9 and 14</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Brain Metastases, Adult</condition>
  <condition>Primary Brain Tumor</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Namzaric® arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1 will take daily Namzaric® for 17 weeks, including 3 weeks of dose-escalation, 12 weeks at a stable dose, and a 2 week taper.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm 2 will take daily placebo for 17 weeks, including 3 weeks of dose-escalation, 12 weeks at a stable dose, and a 2 week taper.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Namzaric®</intervention_name>
    <description>Namzaric® will be given for 17 weeks using the following dosing schedule:&#xD;
7 mg memantine hydrochloride and 10 mg donepezil hydrochloride for 1 week, 14 mg memantine hydrochloride and 10 mg donepezil hydrochloride for 1 week, 21 mg memantine hydrochloride and 10 mg donepezil hydrochloride for 1 week, 28 mg memantine hydrochloride and 10 mg donepezil hydrochloride for 12 weeks, 14 mg memantine hydrochloride and 10 mg donepezil hydrochloride for 1 week, 7 mg memantine hydrochloride and 10 mg donepezil hydrochloride for 1 week.</description>
    <arm_group_label>Namzaric® arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo drug, which will look identical to commercial Namzaric®, will be given for 17 weeks including a 3 week dose-escalation, 12 week maintenance period, and 2 week taper.</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Cancer survivors who received cranial irradiation including, but not limited to,&#xD;
             primary brain tumor, brain metastases, lung cancer receiving prophylactic brain&#xD;
             irradiation, long-term survivors of pediatric cancers&#xD;
&#xD;
          2. Completed a course of fractionated partial brain irradiation or whole brain&#xD;
             irradiation of at least 30 (Gray) Gy more than 6 months prior to enrollment&#xD;
&#xD;
          3. Age ≥ 18 years at the time of entry into the study&#xD;
&#xD;
          4. Karnofsky performance score (KPS) ≥ 70 or Eastern Cooperative Oncology Group (ECOG)&#xD;
             grade ≤ 2.&#xD;
&#xD;
          5. No imaging evidence of disease progression within 4 months of enrollment&#xD;
&#xD;
          6. Life expectancy &gt; 6 months&#xD;
&#xD;
          7. Access to a smartphone, tablet, or computer with capability to utilize the mobile&#xD;
             symptom-tracking application&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active psychiatric illness&#xD;
&#xD;
          2. Clinically significant renal disease or insufficiency at the time of screening&#xD;
&#xD;
          3. History of severe liver disease or laboratory values for liver function tests &gt; 2.5&#xD;
             times the upper limit of normal at screening&#xD;
&#xD;
          4. Use of cognition-enhancing medications at the time of screening. If patients have used&#xD;
             cognition-enhancing medications in the past, a wash-out period can be considered for&#xD;
             screening of 8 weeks at the discretion of the PI.&#xD;
&#xD;
          5. Allergy to Namzaric or any of the components of Namzaric.&#xD;
&#xD;
          6. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine Peters, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katherine Peters, MD, PhD</last_name>
    <phone>919-684-5301</phone>
    <email>dukebrain1@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Woodring</last_name>
    <phone>919-684-5301</phone>
    <email>dukebrain1@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Katherine Peters, MD, PhD</last_name>
      <phone>919-684-5301</phone>
      <email>dukebrain1@dm.duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Woodring</last_name>
      <phone>919-684-5301</phone>
      <email>dukebrain1@dm.duke.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.dukehealth.org/clinical-trials</url>
    <description>Duke Health Clinical Trials</description>
  </link>
  <link>
    <url>https://tischbraintumorcenter.duke.edu/</url>
    <description>The Preston Robert Tisch Brain Tumor Center</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 23, 2020</study_first_submitted>
  <study_first_submitted_qc>September 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2020</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pro00102684</keyword>
  <keyword>Katherine Peters</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Brain metastases</keyword>
  <keyword>Brain tumor</keyword>
  <keyword>Radiation</keyword>
  <keyword>Solid tumor</keyword>
  <keyword>Namzaric®</keyword>
  <keyword>Cognition</keyword>
  <keyword>Pediatric Cancer</keyword>
  <keyword>Cancer Survivor</keyword>
  <keyword>Survivorship</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

